The company said that FTI, a combination of fosfomycin and tobramycin, is ready for Phase III clinical trials, having completed a Phase II trial in CF patients.
FTI is formulated as a liquid for inhalation with an aerosol device.
In Phase II trials, FTI, which is formulated as a liquid for inhalation with an aerosol device, was shown to be safe and to effectively maintain improvement in lung function achieved with Cayston in CF patients with Pseudomonas aeruginosa infection.
FTI has showed antibiotic activity against multiple pathogenic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), in preclinical studies.
CURx founder and CEO Dinu Sen said this is a great acquisition for the company which allows it to expand its portfolio and also to provide another inhaled therapeutic to the cystic fibrosis community.
"Clinical trials in CF patients with Pseudomonas aeruginosa infection have demonstrated FTI’s safety and efficacy," Sen said.
"Future trials may pave the way for its use against a range of bacterial infections in CF – there is an unmet need for antibiotics with such characteristics."